Transl Clin Pharmacol.  2023 Jun;31(2):95-104. 10.12793/tcp.2023.31.e7.

Safety and pharmacokinetic comparison between fenofibric acid 135 mg capsule and 110 mg entericcoated tablet in healthy volunteers

• Seo YB
• Kim JH
• Song JH
• Jung W
• Nam KY
• Kim N
• Choi YW
• Cho S
• Ki DH
• Lee HJ
• Moon J
• Lee S
• Kim J
• Hong JH
• Jung S
• Jung JG

• KMID: 2552410
• DOI: http://doi.org/10.12793/tcp.2023.31.e7

Abstract

This study aimed to compare the pharmacokinetic (PK) and safety profiles of 2 fenofibric acid formulations under fasting and fed conditions. The reference was a 135 mg capsule, while the test was a 110 mg enteric-coated tablet. This randomized, open-label, two-sequence, two-period crossover phase 1 clinical trial was conducted in healthy Korean men. Sixty participants were enrolled in each of the fasting and feeding groups. Blood samples were collected 72 hours after drug administration. PK parameters were calculated using a noncompartmental method with Phoenix WinNonlin ^® . A total of 53 and 51 participants from the fasting and feeding groups, respectively, completed the study. The geometric mean ratio and 90% confidence intervals of the maximum concentration (C _max ) and area under the concentration-time curve to the last measurable plasma concentration were 0.9195 (0.8795–0.9614) and 0.8630 (0.8472–0.8791) in the fasting study and 1.0926 (1.0102–1.1818) and 0.9998 (0.9675–1.0332) in the fed study, respectively. The time to reach C _max of the enteric-coated tablet compared to that of the capsule was extended by 1 and 3 hours under fasting and fed conditions, respectively. In conclusion, enteric-coated tablets have a higher bioavailability than capsules. In addition, the enteric-coated tablet was smaller than the capsule, making it easier for patients to swallow.

Keyword

Dyslipidemias; Dyslipidemias; Pharmacokinetics; Pharmacokinetics; Drug Compounding; Drug Compounding; Biological Availability; Biological Availability; Clinical Trials; Clinical Trials; Phase I as Topic; Phase I as Topic